Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance

BACKGROUND: Despite the remarkable success of immunotherapy in treating melanoma, understanding of the underlying mechanisms of resistance remains limited. Emerging evidence suggests that upregulation of tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Jamaal L, Taylor, Brandie C, Axelrod, Margaret L, Sun, Xiaopeng, Guerin, Lindsey N, Gonzalez-Ericsson, Paula I, Wang, Yu, Sanchez, Violeta, Fahey, Catherine, Sanders, Melinda E, Xu, Yaomin, Hodges, Emily, Johnson, Douglas B, Balko, Justin M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660662/
http://dx.doi.org/10.1136/jitc-2023-007736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660662/
http://dx.doi.org/10.1136/jitc-2023-007736

Ejemplares similares